Developing a vaccine to prevent urogenital schistosomiasis
Official title: Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield
Funded at Pai Life Sciences, INC. · NIH-10818259 · Data updated 2026-11-12
This study is testing a new vaccine to help prevent urogenital schistosomiasis, a disease caused by parasitic worms that can lead to serious health problems, and it's looking for participants to help see how well it works and if it's safe for different groups of people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pai Life Sciences, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | January 3, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,386 |
| NIH project number | 1R41AI181069-01 |
| Project ID | NIH-10818259 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals living in regions where schistosomiasis is endemic, particularly women who may be at risk of infection.
✕Less likely to help
Patients who are not at risk for schistosomiasis or those who have already been treated for the infection may not receive any benefit from this research.
What this research studies
This research focuses on creating a vaccine to combat urogenital schistosomiasis, a disease caused by parasitic worms that can lead to severe health issues, including bladder cancer. The team aims to leverage their previous work on a successful vaccine for a related parasite, using a specific antigen and an adjuvant to enhance the immune response. The research involves testing this new vaccine in clinical trials to ensure its safety and effectiveness in preventing infections. Patients may be involved in trials to assess the vaccine's performance and safety in diverse populations.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of urogenital schistosomiasis and its associated complications.
How similar studies have gone: Previous research has shown success with similar vaccine approaches for related schistosomiasis infections, indicating a promising avenue for this new vaccine.
Where this research is happening
-
Pai Life Sciences, INC.
Seattle, United States Active
Researchers
- Principal investigator: Gray, Sean Alex — Pai Life Sciences, INC.
- Study coordinator: Gray, Sean Alex
Related research
Other NIH-funded projects on the same topics.
-
TLR4-based mucosal melanoma immunotherapy formuation study
A new immune-activating treatment using a TLR4 agonist is being studied to boost anti-tumor responses in mucosal melanoma.
-
A Vaccine for Lymphatic Filariasis (LFGuard) for Adults
A new LF vaccine (LFGuard) aims to help adults in at-risk regions by preventing infection and supporting current mass drug administration efforts.
-
A vaccine to prevent lymphatic filariasis
This study is working on a new vaccine to help protect people from lymphatic filariasis, a disease caused by parasitic worms that affects many around the world, and it aims to provide lasting protection alongside current treatments.
-
Development of a new vaccine for schistosomiasis
This study is testing a new vaccine called SchistoShield® to help protect people from schistosomiasis, a disease caused by parasites that affects many around the world, and it's designed to be safer and more effective than current treatments that aren't working as well anymore.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.